PERSONALISING CARE: USING INFLIXIMAB DRUG TROUGH AND ANTI-DRUG ANTIBODY LEVELS IMPROVES CLINICAL TREATMENT DECISIONS AND IS A COST EFFECTIVE STRATEGY IN SPONDYLOARTHRITIS

被引：0
|
作者：
Dubash, S. [1 ,2 ]
Bryer, D. [1 ,2 ]
Fitton, J. [1 ,2 ]
Barr, A. [1 ,2 ]
Vandevelde, C. [1 ,2 ]
Marzo-Ortega, H. [1 ,2 ]
Freeston, J. [1 ,2 ]
机构：
[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Rheumatol, Leeds, W Yorkshire, England
[2] Leeds Teaching Hosp NHS Trust, NIHR Leeds Biomed Res Ctr, Rheumatol, Leeds, W Yorkshire, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.3116
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0846
引用
收藏
页码：1551 / 1552
页数：2
相关论文
共 50 条
  • [1] PERSONALISING CARE: USING INFLIXIMAB DRUG TROUGH AND ANTI-DRUG ANTIBODY LEVELS IS A SAFE AND COST EFFECTIVE TREATMENT STRATEGY IN SPONDYLOARTHRITIS
    Dubash, S.
    Bryer, D.
    Fitton, J.
    Barr, A.
    Vandevelde, C.
    Marzo-Ortega, H.
    Freeston, J. E.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 731 - 731
  • [2] PERSONALISING CARE: THE USE OF ANTI-DRUG ANTIBODIES AND DRUG TROUGH LEVELS IS A SAFE AND COST-EFFECTIVE TREATMENT STRATEGY IN SPONDYLOARTHRITIS
    Dubash, S. R.
    Bryer, D.
    Fitton, J.
    Barr, A.
    Wenham, C.
    Marzo-Ortega, H.
    Freeston, J. E.
    [J]. RHEUMATOLOGY, 2018, 57
  • [3] Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment
    Patil, Abhishek
    Upadhyaya, Sundeep
    Dawar, Reetika
    Dadhaniya, Nikunjkumar
    Sood, Isha
    Gupta, Sirinder J.
    Handa, Rohini
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (09) : 1638 - 1643
  • [4] Clinical Outcome of Pediatric IBD Patients After Measurement of Infliximab Drug and Anti-Drug Antibody Levels
    Turon, Joanna
    Langseder, Annette
    Irizarry, Ruth
    Ahuja, Komal
    Rosh, Joel R.
    [J]. GASTROENTEROLOGY, 2013, 144 (05) : S531 - S531
  • [5] Evaluation of Immunoassays for the Detection of Anti-Drug Antibodies Against Infliximab and the Corresponding Drug Levels in Patients with Spondyloarthritis in Clinical Practice
    Von Bremen, Helene
    Gamboa, Lorena Martinez
    Zernicke, Jan
    Poddubnyy, Denis
    Feist, Eugen
    [J]. AKTUELLE RHEUMATOLOGIE, 2021, 46 (05) : 465 - 473
  • [6] Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions
    Goldberg, R.
    Beswick, L.
    Van Langenberg, D.
    Sally, B.
    Rosella, O.
    Gibson, P.
    Moore, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S223 - S223
  • [7] Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier
    Kharlamova, Nastya
    Hermanrud, Christina
    Dunn, Nicky
    Ryner, Malin
    Hambardzumyan, Karen
    Pomiano, Nancy Vivar
    Marits, Per
    Gjertsson, Inger
    Saevarsdottir, Saedis
    Pullerits, Rille
    Fogdell-Hahn, Anna
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [8] INFLIXIMAB TROUGH LEVELS AND ANTI-DRUG ANTIBODIES AFTER INDUCTION AS PREDICTIVE FACTORS OF LONG TERM CLINICAL REMISSION
    Bodini, G.
    Del Nero, L.
    Giannini, E.
    De Maria, C.
    Baldissarro, I
    Savarino, V
    Savarino, E.
    [J]. DIGESTIVE AND LIVER DISEASE, 2016, 48 : E163 - E163
  • [9] Infliximab Assay Used in Clinical Practice Validated for Measuring SB2 Infliximab Biosimilar's Serum Drug and Anti-drug Antibody Levels
    Noguier, Guillaume
    Daviere, Simon
    Elouardani, Samia
    Veldet, Can
    Ticaud, Thierry
    Parussini, Ermis
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S398 - S398
  • [10] The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
    Neasa Mc Gettigan
    Aman Shah Afridi
    Grace Harkin
    Caroline Lardner
    Stephen Patchett
    Danny Cheriyan
    Gavin Harewood
    Karen Boland
    Aoibhlinn O’Toole
    [J]. International Journal of Colorectal Disease, 2021, 36 : 1231 - 1241
12345